A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic Sarcoma

NCT05193214 ↗

Phase 2 Unknown 30 enrolled Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to evaluate the efficacy and safety of recombinant anti-PD-1 humanized monoclonal antibody injection (609A) in patients with unresectable or advanced undifferentiated pleomorphic sarcoma

Timeline

Start: 2022-01-25
Primary completion: 2023-12-31
Completion: 2024-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	609A	Monoclonal antibody	200 mg	Intravenous

A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic Sarcoma

Summary

Timeline

Drugs

Indications